Cymbalta Advisory Committee Review In Chronic Pain Now Set For August
This article was originally published in The Pink Sheet Daily
Executive Summary
Rescheduled panel meeting could include discussion of statistical methods for dealing with missing patient data and safe use in a significantly broader population.
You may also be interested in...
Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning
The new indication for Lilly's SNRI would expose a much larger patient population to the risk of liver injury. The FDA reviewer and his supervisors disagree about how to handle the concern.
Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning
The new indication for Lilly's SNRI would expose a much larger patient population to the risk of liver injury. The FDA reviewer and his supervisors disagree about how to handle the concern.
Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data
A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs